Antiviral Briefs. AIDS patient care STDS. 1996; 10, 307–309.

Kamp W, et al. Effect of weekly adefovir (PMEA) infusions on HIV-1 virus load: results of a phase I/II study. Antivir Ther. 1999;4:101–7.

Article  CAS  PubMed  Google Scholar 

Snedecor SJ, Sullivan SM, Ho RJY. Feasibility of weekly HIV drug delivery to enhance drug localization in lymphoid tissues based on pharmacokinetic models of lipid-associated indinavir. Pharm Res. 2006;23:1750–5.

Article  CAS  PubMed  Google Scholar 

Fisk-Hoffman RJ, et al. Who wants long-acting injectable antiretroviral therapy? Treatment preferences among adults with HIV in Florida. AIDS Care. 2024;36(11):1545–54. https://doi.org/10.1080/09540121.2024.2383872.

Article  CAS  PubMed  Google Scholar 

Moreno C, et al. Acceptability of Long-acting injectable antiretroviral treatment for HIV management: perspectives of patients and physicians in Spain. AIDS Patient Care and STDs. 2024;38(7):305–14.

Article  PubMed  Google Scholar 

Dandachi D, Dang BN, Lucari B, Swindells S, Giordano TP. Acceptability and preferences for long-acting antiretroviral formulations among people with HIV infection. AIDS Care. 2021;33:801–9.

Article  PubMed  Google Scholar 

Fifer S, Kularatne T, Tan M, Drummond F, Rule J. Understanding treatment preferences among people living with HIV in Australia: a discrete choice experiment. Patient Prefer Adherence. 2023;17:1825–43.

Article  PubMed  PubMed Central  Google Scholar 

Collins LF, et al. Interest in and preference for long-acting injectable antiretroviral therapy in the era of approved cabotegravir/rilpivirine among reproductive-aged women in the US south. Clin Infect Dis. 2024;ciae331. https://doi.org/10.1093/CID/CIAE331.

Feihel D, Spier D, Stevens T, Stefanov DG, Ahmadi L. Acceptance rate and reasons for rejection of long acting injectable antiretrovirals. AIDS Behav. 2023;27:2370–5.

Article  PubMed  Google Scholar 

Dubé K, et al. Reasons people living with HIV might prefer oral daily antiretroviral therapy, long-acting formulations, or future HIV remission options. AIDS Res Hum Retroviruses. 2020;36:1054–8.

Article  PubMed  PubMed Central  Google Scholar 

Kremer IEH, et al. Preferences of people living with HIV for injectable and oral antiretroviral treatment in the Netherlands: a discrete choice experiment. AIDS Care. 2024;36:536–45.

Article  PubMed  Google Scholar 

Celesia M, et al. Long-acting drugs: people’s expectations and physicians’ preparedness. Are we readying to manage it? An Italian survey. Medicine. 2022;101(42):e30052.

Article  PubMed  PubMed Central  Google Scholar 

Williams J, et al. Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients. Nanomedicine (Lond). 2013;8:1807–13.

Article  CAS  PubMed  Google Scholar 

Weld ED, et al. Interest of youth living with HIV in long-acting antiretrovirals. J Acquir Immune Defic Syndr. 2019;80:190–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

de los Rios, P. et al. Treatment aspirations and attitudes towards innovative medications among people living with HIV in 25 countries. Popul Med. 2020; 2, 1–13 .

Palacios C, et al. Expectations and acceptability of long-acting injectable antiretrovirals by patients living with HIV/AIDS. Infect Dis Now. 2022;52:238–9.

Article  PubMed  Google Scholar 

Emmert M, Rohrbacher S, Jahn J, Fernando K, Lauerer M. Preferences of people living with HIV for long-acting antiretroviral treatment in Germany: evidence from a discrete choice experiment. Patient. 2023;16:537–53.

Article  PubMed  PubMed Central  Google Scholar 

Schmidt D, Kollan C, Stoll M. Long-acting prescriptions and therapy for HIV-1 from market launch to the present in Germany (May 2021 to December 2023). Front Public Health. 2024;12:1404255.

Article  PubMed  PubMed Central  Google Scholar 

Stout JA, et al. Engagement in care, awareness, and interest in long-acting injectable anti-retroviral therapy. AIDS Behavior. 2024;28(10):3315–25.

Article  PubMed  Google Scholar 

Barthold D, et al. Preference for daily oral pills over long-acting antiretroviral therapy options among people with HIV. AIDS. 2023;37:1545–53.

Article  CAS  PubMed  Google Scholar 

Campbell CK, et al. LAI-ART awareness, willingness, barriers and facilitators among black sexual minority men living with HIV in the US South. Int J Environ Res Public Health. 2024;21(5):602.

Article  PubMed  PubMed Central  Google Scholar 

Philbin MM, et al. Multisite study of women living with HIV’s perceived barriers to, and interest in, long-acting injectable antiretroviral therapy. J Acquir Immune Defic Syndr. 2020;84:263–70.

Article  PubMed  PubMed Central  Google Scholar 

Sluis-Cremer N, et al. E138A in HIV-1 reverse transcriptase is more common in subtype C than B: implications for rilpivirine use in resource-limited settings. Antiviral Res. 2014;107:31–4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maruapula D, et al. Archived rilpivirine-associated resistance mutations among ART-naive and virologically suppressed people living with HIV-1 subtype C in Botswana: implications for cabotegravir/rilpivirine use. J Antimicrob Chemother. 2023;78:2489–95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Agarwal H, et al. ‘I feel like i don’t even have HIV anymore’-facilitators, barriers, and experience regarding use of long-acting injectable antiretroviral therapy among persons with HIV in North Carolina. AIDS Patient Care STDS. 2024;38:324–9.

Article  PubMed  Google Scholar 

Rodriguez HG, et al. ‘What is the benefit?’: Perceptions and preferences for long-acting injectable antiretroviral therapy among people living with HIV. AIDS Educ Prev. 2023;35:467–83.

Article  PubMed Central  Google Scholar 

Dubé K, et al. The dose response: perceptions of people living with HIV in the United States on alternatives to oral daily antiretroviral therapy. AIDS Res Hum Retroviruses. 2020;36:324–48.

Article  PubMed  PubMed Central  Google Scholar 

Christopoulos KA, et al. Are patients and their providers talking about long-acting injectable antiretroviral therapy? Penetration into clinical encounters at three U.S. care sites. Open Forum Infect Dis. 2022;9:ofac293.

Article  PubMed  PubMed Central  Google Scholar 

Jaiswal J, et al. ‘Worn out’: coping strategies for managing antiretroviral treatment fatigue among urban people of color living with HIV who were recently disengaged from outpatient HIV care. J HIV AIDS Soc Serv. 2020;19:173–87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chounta V, et al. Patient-reported outcomes through 1 year of an HIV-1 clinical trial evaluating long-acting cabotegravir and rilpivirine administered every 4 or 8 weeks (ATLAS-2M). Patient. 2021;14:849–62.

Article  PubMed  PubMed Central  Google Scholar 

Murray M, et al. Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study. HIV Res Clin Pract. 2019;20:111–22.

Article  CAS  PubMed  Google Scholar 

Zhang H, et al. Combination of long-acting HIV fusion inhibitor albuvirtide and LPV/r showed potent efficacy in HIV-1 patients. AIDS Res Ther. 2016;13:1–4.

Article  Google Scholar 

Su B, et al. Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study. Chin Med J (Engl). 2020;133:2919–27.

Article  CAS  PubMed  Google Scholar 

Chen Z, et al. A case of multiple ART intolerance responds to Albuvirtide and Dolutegravir: case report and literature review. Heliyon. 2024;10(6):e27219.

Article  PubMed